New ICD-10 Codes Will Help the T1D Community
On October 1st, the T1D community got a big win: the Centers for Medicare and Medicaid Servies (CMS) introduced a unique ICD-10 code for stage 2 type 1 diabetes (T1D). This addresses a significant gap in clinical care. Prior to this change, clinicians had limited options for coding stage 2 T1D, which resulted in inaccurate […]
At ADA 2024, Breakthrough T1D-funded research takes center stage
Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary of Breakthrough T1D highlights.
ADA Takeaways: Day 2
At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for the T1D community.
Breakthrough T1D spearheads the formation of monitoring guidelines
We spearheaded an effort to develop the first internationally agreed-upon guidance for anyone who tests positive for T1D autoantibodies.
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
C-Peptide as an Endpoint in Clinical Trials: Its Time Has Come
A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in T1D.
Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.
ATTD Brings Together Top Minds in Diabetes Research
Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.
Top Researchers Gather for the 17th ATTD Conference
This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50 Breakthrough T1D-funded presenters.
Breakthrough T1D T1D Fund Invests in vTv Therapeutics
With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.
